An Exploratory, Randomized, Double-blind, Placebo-controlled, Parallel Arm Trial of the Safety and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Patients Hospitalized With Worsening Heart Failure
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2018
At a glance
- Drugs Sotagliflozin (Primary)
- Indications Heart failure
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi
- 31 Aug 2018 Biomarkers information updated
- 13 Jul 2018 Planned End Date changed from 22 Mar 2019 to 22 Nov 2019.
- 13 Jul 2018 Planned primary completion date changed from 22 Mar 2019 to 22 Nov 2019.